4 active not recruiting, 3 completed, 1 recruiting, 1 terminated. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow IO Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors IO102-IO103, Pembrolizumab KEYTRUDA® - Melanoma, Squamous Cell Carcinoma of Head and Neck | Phase 2 | Recruiting | IO Biotech | 60 | 2023-12-21 | 2024-03-18 |
| Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). Pembrolizumab, IO102-103 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2023-12-14 | 2026-09-22 |
| A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma IO102/IO103, Nivolumab-Relatlimab - Melanoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 43 | 2023-06-09 | 2026-06-01 |
| IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer PD-L1/IDO Peptide Vaccine, Pembrolizumab - High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 | Active not recruiting | University of California, Davis | 6 | 2023-04-19 | 2026-07-16 |
| IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) IO102-IO103, Pembrolizumab - Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Active not recruiting | IO Biotech | 407 | 2022-05-17 | 2025-08-28 |
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC IO102-IO103 in combination with pembrolizumab - Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | IO Biotech | 63 | 2022-04-11 | 2026-04-08 |
| Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. PD-L1, PD-L2 peptides with Montanide ISA51 - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Lars Møller Pedersen | 19 | 2019-04-26 | 2022-02-21 |
| PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma PD-L1 peptide - Smoldering Multiple Myeloma | Phase 2 | Terminated | Lene Meldgaard Knudsen | 6 | 2019-02-18 | 2022-04-15 |
| IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC IO102, pembrolizumab (Keytruda), Carboplatin (Carboplatin Kabi) - NSCLC | Phase 1 / Phase 2 | Completed | IO Biotech | 109 | 2018-08-22 | 2022-04-21 |
Melanoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Neoplasms, Plasma Cell (1) · Smoldering Multiple Myeloma (1) · Urinary Bladder Neoplasms (1)
pembrolizumab (6) · Carboplatin (1) · Opdualag (1) · Pemetrexed (1) · montanide ISA 51 (1)
United States (6) · Denmark (4) · Spain (4) · Germany (3) · United Kingdom (3) · Australia (2) · France (2) · Netherlands (2) · Belgium (1) · Czechia (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · South Africa (1)
Barbara Burtness, MD, Prof (1) · Inge Marie Svane, MD, Prof (1) · James Smithy, MD (1) · James Spicer, MD Prof (1) · Jonathan W Riess, MD, MSc (1) · Mamta Parikh (1) · Uffe M Klausen, MD (1) · Wojciech K Mydlarz, M.D., FACS (1)
2018 (3), P30CA093373 (1)